Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Episodic Migraine clinical trials
7 of 14 indexed Episodic Migraine trials are currently recruiting.
14 US clinical trials · 7 currently recruiting
Episodic Migraine is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 9 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Click Therapeutics, running 2 of these trials.
The research picture
Episodic Migraine has 14 registered US clinical trials, 7 of them open to new participants right now, about 50% of the total.
- 7
- recruiting participants now
- 50%
- of trials open to enrollment
- 9
- in Phase 3–4 (later-stage)
- 2
- top sponsor: Click Therapeutics
Active & Recent Trials
14 total, page 1 of 1
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
Merz Therapeutics
NCT07018700
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Hospital Universitari Vall d'Hebron Research Institute
NCT07159750
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
Ipsen
NCT06625060
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
AbbVie
NCT05711394
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
H. Lundbeck A/S
NCT05897320
Chiropractic Care for Episodic Migraine
Brigham and Women's Hospital
NCT06229834
Efficacy of Nerve Blocks for Episodic Migraine
Mayo Clinic
NCT05734625
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
Ipsen
NCT06047457
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
Eli Lilly and Company
NCT03432286
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
Amgen
NCT03927144
A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine
Eli Lilly and Company
NCT05127486
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Click Therapeutics
NCT05853900
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine Receiving CGRP Therapy (ReMMiD-C)
Click Therapeutics
NCT06004388
The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache
Beth Israel Deaconess Medical Center
NCT00719134
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 6 |
| Phase 4 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Episodic Migraine Trial Landscape
14 indexed Episodic Migraine studies · 7 recruiting (50%).
Phase mix: 9 late (III/IV) vs 2 early (I/II).
Top sponsor: Click Therapeutics (2 trials), 9 others listed. 14 shown below, recruiting first.
How to read this condition's trial landscape
That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation, eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Episodic Migraine?
PlainTrial tracks 14 US clinical trials for Episodic Migraine, of which 7 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Episodic Migraine?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.